Opinion statement
Cholestatic liver disease affects a small percentage of children, but therapy results in millions of healthcare dollars being spent each year. Close monitoring of nutritional status, pruritus, and complications from portal hypertension should improve the patient’s quality of life and survival without liver transplantation. Other comorbid conditions, such as cardiac or renal disease, must also be integrated into the care plan and will affect the overall prognosis of the patient. Portal hypertension leads to ascites, variceal hemorrhage, and infection, which can result in significant mortality if not promptly recognized and treated. Surgical shunts are being used less because the expertise to perform endoscopic sclerotherapy and endoscopic band ligation is available at most medical centers. However, many cholestatic diseases, including biliary atresia, progressive familial intrahepatic cholestasis (PFIC) I, II, and III, and Alagille syndrome, may still require liver transplantation (Table 1). The cost of this procedure can exceed several hundred thousand dollars per patient, without including the annual costs of immunosuppressant therapy and medical monitoring. Meticulous medical management of nutrition and the sequelae of portal hypertension may prolong survival and reduce the potential morbidity and mortality of liver transplantation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Ng VL, Ryckman FC, Porta G, et al.: Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000, 30:152–156.
Emerick KM, Whitington PF: Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002, 35:1501–1506. Largest series of Alagille patients undergoing partial external biliary diversion with improvement or resolution of pruritus and xanthomas. Average follow-up time was 7.5 years.
Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, et al.: Ileal exclusion for Byler’s disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998, 33:220–224.
Heubi JE, Wiechmann DA, Creutzinger V, et al.: Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr 2002, 141:237–242. First pediatric controlled trial to determine if tauroursodeoxycholic acid prevents TPN cholestasis. This study failed to show efficacy and the authors advocated the creation of an intravenous preparation that might offer protection from TPN cholestasis.
Jacquemin E, Hermans D, Myara A, et al.: Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997, 25:519–523.
Narkewicz MR, Smith D, Gregory C, et al.: Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998, 26:49–55.
D’Antiga L, Moniz C, Buxton-Thomas M, et al.: Bone mineral density and height gain in children with chronic cholestatic liver disease undergoing transplantation. Transplantation 2002, 73:1788–1793.
Guthery SL, Pohl JF, Bucuvalas JC, et al.: Bone mineral density in long-term survivors following pediatric liver transplantation. Liver Transpl 2003, 9:365–370.
Evans S, Stovroff M, Heiss K, et al.: Selective distal splenorenal shunts for intractable variceal bleeding in pediatric portal hypertension. J Pediatr Surg 1995, 30:1115–1118.
Longo M, Crosignani A, Battezzati PM, et al.: Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002, 51:265–269.
Suchy FJ, Sokol RJ, Balistreri WF: Liver Disease in Children, edn 2. Philadelphia: Lippincott Williams & Wilkins; 2001.
Sokol RJ, Stall C: Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr 1990, 52:203–208.
Sokol RJ, Heubi JE, McGraw C, et al.: Correction of vitamin E deficiency in children with chronic cholestasis. II. Effect on gastrointestinal and hepatic function. Hepatology 1986, 6:1263–1269.
Davit-Spraul A, Cosson C, Couturier M, et al.: Standard treatment of alpha-tocopherol in Alagille patients with severe cholestasis is insufficient. Pediatr Res 2001, 49:232–236. Standard dosages of fat-soluble vitamins may not be suitable for all cholestatic patients.
Bucuvalas JC, Heubi JE, Specker BL, et al.: Calcium absorption in bone disease associated with chronic cholestasis during childhood. Hepatology 1990, 12:1200–1205.
Alaimo K, McDowell MA, Briefel RR, et al.: Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988–1991. Adv Data 1994, 258:1–28.
Heubi JE, Higgins JV, Argao EA, et al.: The role of magnesium in the pathogenesis of bone disease in childhood cholestatic liver disease: a preliminary report. J Pediatr Gastroenterol Nutr 1997, 25:301–306.
Yerushalmi B, Sokol RJ, Narkewicz MR, et al.: Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999, 29:442–447.
Wolfhagen FH, Sternieri E, Hop WC, et al.: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997, 113:1264–1269.
Balsells F, Wyllie R, Steffen R, Kay M: Benign recurrent intrahepatic cholestasis: improvement of pruritus and shortening of the symptomatic phase with rifampin therapy: a case report. Clin Pediatr 1997, 36:483–485.
Klein GL, Soriano H, Shulman RJ, et al.: Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant 2002, 6:136–140.
Kramer RE, Sokol RJ, Yerushalmi B, et al.: Large-volume paracentesis in the management of ascites in children. J Pediatr Gastroenterol Nutr 2001, 33:245–249.
Shashidhar H, Langhans N, Grand RJ: Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study. J Pediatr Gastroenterol Nutr 1999, 29:12–17.
Del Puppo M, Galli Kienle M, Crosignani A, et al.: Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001, 42:437–441.
Prince MI, Burt AD, Jones DE: Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002, 50:436–439.
D’Amico G, Pietrosi G, Tarantino I, et al.: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: A cochrane meta-analysis. Gastroenterology 2003, 124:1277–1291.
Larrosa-Haro A, Saenz-Rivera C, Gonzalez-Ortiz M, et al.: Lack of cholesterol-lowering effect of graded doses of cholestyramine in children with Alagille syndrome: a pilot study. J Pediatr Gastroenterol Nutr 2003, 36:50–53.
Miga D, Sokol RJ, Mackenzie T, et al.: Survival after first esophageal variceal hemorrhage in patients with biliary atresia. J Pediatr 2001, 139:291–296.
McKiernan PJ: A prospective study of endoscopic esophageal variceal ligation using a multiband ligator. J Pediatr Gastroenterol Nutr 2002, 34:207–211.
Melter M, Rodeck B, Kardorff R, et al.: Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am J Gastroenterol 2000, 95:3522–3528.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cohran, V.C., Heubi, J.E. Treatment of pediatric cholestatic liver disease. Curr Treat Options Gastro 6, 403–415 (2003). https://doi.org/10.1007/s11938-003-0043-4
Issue Date:
DOI: https://doi.org/10.1007/s11938-003-0043-4